Consistent with previous observations,1SETBP1 mutations (D868N and G870S) are commonly detected in a variety of myeloid malignancies including AML (Fig. 1G), and co-occurred with genetic alterations involved in spliceosome (SRSF2, U2AF1, SF3B1), epigenetics (ASXL1, EZH2, TP53, TET2, DNMT3A, IDH1/2), kinase signaling (JAK2, NRAS, PTPN11, KRAS, FLT3) (Fig. 1H). Here, FLT3 is linked to acute myeloid leukemia.